Information Provided By:
Fly News Breaks for September 5, 2018
BCRX
Sep 5, 2018 | 07:11 EDT
JMP Securities analyst Liisa Bayko raised her price target on BioCryst to $16 from $12 after data from the Phase 2 ZENITH-1 trial showed the liquid formulation of 750 mg BCX7353 was superior to placebo in multiple clinical outcomes measuring hereditary angioedema attacks. The data for BCX7353 opens the door to the acute treatment setting, Bayko tells investors. She maintains her Outperform rating on BioCryst shares.
News For BCRX From the Last 2 Days
BCRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.